This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016
Practice Guidelines for Treatment of Chronic Hepatitis B (1) and update the previous …

Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …

Abstract Background & Aim Hepatitis B reactivation related to the use of immunosuppressive
therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic …

This article has an accompanying continuing medical education activity on page e16.
Learning Objective: Upon completion of the CME activity, successful learners will be able to …

To achieve the goal of the World Health Organization to eliminate viral hepatitis as a major
public health threat by 2030, the Chinese Society of Infectious Diseases and the Chinese …

中华医学会感染病学分会,中华医学会肝病学分会 Page 1 +,-. 慢性乙型肝炎防治指南(2019 年版
) 中华医学会感染病学分会,中华医学会肝病学分会 摘要:为了实现世界卫生组织提出的“2030 年 …

Diseases (AASLD) also presented and continued to revise their clinical practice guidelines,
and the latest updates were in 2015, 2017, and 2018. However, since the medical …

Background: Single-agent doxorubicin has been widely used to treat unresectable
hepatocellular carcinoma (HCC), but the response rate is low (< 20%) and there is no …

Patients with chronic HBV infection are at risk of reactivation of HBV should they require
immunosuppressive therapies for a variety of clinical settings, including chemotherapy for …

Objective: A randomized controlled trial was conducted to find out whether antiviral therapy
in patients with hepatitis B–related hepatocellular carcinoma (HCC) improves long-term …